TALOS THERAPEUTICS, INC.

Talos Therapeutics, Inc. is a biopharmaceutical company focused on the research, development, and clinical translation of novel therapeutic candidates for unmet medical needs. Their core capabilities center on early- to mid-stage drug discovery, molecular target validation, and preclinical development of small molecule and biologic therapeutics. The company demonstrates specialized expertise in pharmacokinetic and pharmacodynamic modeling, IND-enabling toxicology studies, and formulation science tailored for oncology, immunology, and central nervous system indications. Their technical approach integrates structure-based drug design, high-throughput screening, and translational biomarker development to accelerate candidate progression from bench to clinic. Differentiators include a proprietary platform for targeting previously undruggable pathways and a strong emphasis on mechanistic rigor in lead optimization. No award history is available to infer specific agency engagements or government contract performance. Consequently, there is no discernible pattern of work with federal agencies or public sector clients. The company operates within the biotechnology and pharmaceutical development sector, with primary activity aligned to NAICS categories related to research and development in the life sciences. In practice, this means advancing novel therapeutics through preclinical stages toward regulatory submission, with a market positioning focused on innovation-driven drug candidates rather than commercial manufacturing or distribution. Talos Therapeutics, Inc. is structured as a small, privately held entity (2L) headquartered in San Diego, California. The company holds no government certifications, including 8(a), HUBZone, or WOSB status. Its geographic presence is localized to its San Diego facility, with no public indication of federal contract performance or government market participation. The business remains focused on private-sector R&D investment and scientific innovation.